Will the CSL share price crack the $300 barrier this week?

The CSL Limited (ASX: CSL) share price could break the $300 barrier this week – is there still time to buy the healthcare group for growth?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has started the new decade exactly how it finished the last – rocketing higher.

The healthcare group's shares closed at $299.30 per share last Friday and set a new all-time high in the process.

Why you should watch the CSL share price this week

There's a good chance the CSL share price could finally breach the $300 per share barrier for the first time ever.

That would be an impressive start to the new year, given the healthcare group's shares are up a whopping 38,973% since its IPO.

CSL listed on the ASX in 1994 for an adjusted 3-for-1 stock split price of just 76.6 cents per share. That means an investor who bought and held $10,000 worth of CSL shares since the IPO would be sitting on $3,897,310.70 today.

Of course, most investors would have sold their shares well short of today's all-time high. But if you were a true long-term buy-and-hold investor, that is a very tidy return from the CSL share price.

Where can I find the next CSL?

That is the multi-million-dollar question everyone would love an answer to. There have been several strong ASX growth shares emerge in recent years, all of which have potential.

The most notable ones are the "WAAAX" tech shares including Altium Limited (ASX: ALU), Appen Ltd (ASX: APX) and Xero Limited (ASX: XRO), which have seen similar growth trajectories to the CSL share price.

Outside of these, Nearmap Ltd (ASX: NEA) shares have rocketed higher in the past decade, and it has been a similar story for buy-now, pay-later companies like Zip Co Ltd (ASX: Z1P) and Afterpay Ltd (ASX: APT).

How can I make huge returns on the ASX?

To make the really big money and cash in on share price rises like CSL, you really have to be an IPO investor.

That is more difficult than you think, with evidence showing that you're likely to lose money by investing in IPOs in the long-term.

Of course, if you can ride a winner like CSL all the way to the top, you may only need one ASX growth stock to make your retirement plans a reality.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO, CSL Ltd., and ZIPCOLTD FPO. The Motley Fool Australia owns shares of and has recommended Nearmap Ltd. The Motley Fool Australia owns shares of Altium and Xero. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
Healthcare Shares

CSL, Sonic, and Sigma Healthcare shares: Buy, hold, or sell?

Analysts share their ratings and opinions on 3 large-cap ASX 200 healthcare stocks.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Down 38% in a year, are CSL shares now a buy?

A leading investment expert delivers his verdict on CSL shares.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Healthcare Shares

This Cochlear-backed ASX aspirant will be targeting an epilepsy market worth north of $1 billion

This company is looking to raise $125 million to help commercialise its epilepsy monitoring technology.

Read more »

Surgeon looking at a monitor in an operating room.
Share Market News

Is the only way up for this ASX small-cap healthcare stock?

Bigger returns could be coming for this ambitious small-cap.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Monash IVF has named a new Managing Director to help right the ship

Monash IVF has named a new leader, but she will not start in the top job for some time.

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Macquarie predicts 12% upside for this ASX 200 healthcare stock

Neuren Pharmaceuticals shares have exploded recently.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Healthcare Shares

Mesoblast shares surge 60% in a year. Have investors missed the boat?

Find out if the company is set to experience more growth.

Read more »

a close up of an adult male lion with a large mane fast asleep.
Healthcare Shares

Why this leading fundie is tipping ResMed shares for near-term gains

A top fundie expects a strong near-term rebound from ResMed shares. Let’s see why.

Read more »